UNCY (Unicycive Therapeutics) Moat Score: 2/10 (As of Jul. 07, 2026)


UNCY Unicycive Therapeutics Inc UNCY
32 GF Score
Price $5.09
! 2 Warning Signs
View Full Analysis

What is Unicycive Therapeutics Moat Score?

Unicycive Therapeutics UNCY -5.21% 32 Moat Score is 2 as of Jul. 07, 2026. GuruFocus rates UNCY with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 1,394 Biotechnology companies, Unicycive Therapeutics ranks better than 58.32% on this metric.

Unicycive Therapeutics has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Unicycive Therapeutics has No Moat: Unicycive Therapeutics Inc has minimal competitive advantages. It lacks market leadership, significant intellectual property, and customer loyalty, making it vulnerable to larger competitors.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Unicycive Therapeutics might have No Moat - Very weak/transient advantages.

Unicycive Therapeutics  (NAS:UNCY) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Unicycive Therapeutics Moat Score Related Terms

UNCY vs MDWD, ARCT, NGEN: Moat Score Comparison

For the Biotechnology subindustry, Unicycive Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Unicycive Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Unicycive Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Unicycive Therapeutics's Moat Score falls into.


UNCY
32GF Score
Unicycive Therapeutics Inc UNCY
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Unicycive Therapeutics (UNCY) has a Moat Score of 2 as of Jul. 07, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Unicycive Therapeutics ranks #581 out of 1394 companies in the Biotechnology industry, placing it in the top 41.7%.
Is Unicycive Therapeutics' Moat Score too high?
Unicycive Therapeutics' current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Unicycive Therapeutics' value of 2 is 0% at this industry median. Based on the distribution chart, Unicycive Therapeutics ranks #581 out of 1394 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Unicycive Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Unicycive Therapeutics' Moat Score compare to MDWD and ARCT?
According to the Biotechnology industry distribution chart, Unicycive Therapeutics ranks #581 out of 1394 companies for Moat Score. This puts Unicycive Therapeutics in the upper half of its industry. The industry median Moat Score is 2.00. Unicycive Therapeutics' value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,394 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Unicycive Therapeutics's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Unicycive Therapeutics's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unicycive Therapeutics stock overvalued right now?
Unicycive Therapeutics (UNCY) has a current Moat Score of 2. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Unicycive Therapeutics' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Unicycive Therapeutics (UNCY), the current Moat Score is 2 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Unicycive Therapeutics Business Description

Address 1975 W. El Camino Real, Suite 204, Mountain View, CA, USA, 94040
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.
32GF Score

Get the complete analysis for UNCY

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.09
Price